Antihemophilic factor, recombinant, manufactured protein-free

DRUG5 trials

Sponsors

Baxalta now part of Shire

Conditions

Hemophilia A

Phase 2

Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery

CompletedNCT00157105

Baxalta now part of ShireHemophilia A

Start: 2001-02-12End: 2004-08-03Updated: 2021-08-24

Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

CompletedNCT00157040

Baxalta now part of ShireHemophilia A

Start: 2002-06-07End: 2005-01-04Target: 50Updated: 2021-04-27

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901

CompletedNCT00157053

Baxalta now part of ShireHemophilia A

Start: 2001-11-22End: 2004-08-03Updated: 2021-08-24

Phase 4

Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

CompletedNCT00243386

Baxalta now part of ShireHemophilia A

Start: 2006-01-04End: 2010-06-16Updated: 2021-05-19

Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

CompletedNCT00289536

Baxalta now part of ShireHemophilia A

Start: 2006-02-02End: 2007-04-01Updated: 2021-06-10

Related Papers

Cost Comparison of Efanesoctocog Alfa with Existing Factor VIII Replacement Therapies for Major Surgeries in People with Severe Hemophilia a

Blood2024-11-05